SILO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Silo Pharma Inc (SILO) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance is weak, with significant declines in net income, EPS, and gross margin. While the recent news about government support for psychedelic research aligns with the company's focus, it has not yet translated into strong market momentum or financial improvement. The technical indicators are neutral, and there are no significant trading trends or proprietary trading signals to suggest an immediate buying opportunity.
The MACD is slightly positive at 0.0106 but contracting, indicating weakening momentum. RSI is neutral at 44.666, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 0.527, with key support at 0.407 and resistance at 0.646. Pre-market price is down 4.56%, suggesting bearish sentiment.
Recent executive order by President Trump allocating $50 million for psychedelic research aligns with Silo Pharma's SPC-15 program for PTSD treatment. This could provide long-term growth potential if the company capitalizes on this opportunity.
Weak financial performance in Q4 2025, with significant declines in net income (-49.06% YoY), EPS (-82.05% YoY), and gross margin (-116.07% YoY). Pre-market price drop of 4.56% indicates bearish sentiment.
In Q4 2025, revenue remained flat at 18026 (0.00% YoY), but net income dropped significantly to -881530 (-49.06% YoY). EPS declined to -0.07 (-82.05% YoY), and gross margin fell to -14.77 (-116.07% YoY). Overall, financial performance is weak, with no signs of improvement.
No analyst rating or price target changes available.
